Agency Creative has been named agency of record for Erchonia Corporation. The McKinney-based laser manufacturer has recently announced that the U.S. Food and Drug Administration (FDA) has granted the company 510 (k) clearance to market FX 635, its new low level laser for the relief of chronic heel pain from plantar fasciitis. The Agency Creative team has just completed a multi-channel marketing campaign for the FX 635 that includes trade ads targeting podiatrists, collateral materials, a sales video and website elements.
Erchonia is a global leader in low level laser healthcare applications and solutions. The FX 635 is just the latest in a growing line of low level lasers that treat a variety of issues.
“I couldn’t be happier with the FX 635 launch,” said Charlie Shanks, vice president of Erchonia. “The marketing materials do an exceptional job at demonstrating both the efficacy of this low level laser and its ease of operation.”
Verjú is another low level laser in the Erchonia line for which the Agency team will be developing a multi-channel marketing messaging and materials for the relaunch of this low level laser targeted at the aesthetic industry.
“Unlike FX 635, which is targeted to the podiatry community, Verjú is directed to the health and beauty sector,” explained Mark Wyatt, president and founder of Agency Creative. “It uses this amazing regenerative technology to actually resculpt and contour the human form.”
Verjú offers the aesthetic industry body contouring technology that has been quantitatively verified by clinical studies to remove cellulite and body fat. It, too, has been cleared by the FDA.
The Verjú multi-channel marketing relaunch will include strategic development, public relations, print advertising, digital marketing and more.
“This is the beginning of a very good relationship,” summarized Shanks, “The Agency Creative team has definitely hit the ground running.”